Apr 19 2024 This Week in Cardiology
04/19/24 • 28 min
ACC Part 2: The TACT2 trial of chelation, inter-atrial shunts for HF, and triglyceride lowering; plus diltiazem and Factor Xa anticoagulants are the topics John Mandrola, MD, covers this week.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. TACT 2
Chelation Therapy Provides No Benefit Post-MI
https://www.medscape.com/viewarticle/chelation-therapy-provides-no-benefit-post-mi-2024a10006l5
Chelation Therapy and CV Risk: Why TACT2 Showed No Benefit https://www.medscape.com/viewarticle/chelation-therapy-and-cv-risk-why-tact2-showed-no-benefit-2024a1000761?src=
- JAMA TACT 1 paper https://jamanetwork.com/journals/jama/fullarticle/1672238
- Diabetes Subgroup paper https://pubmed.ncbi.nlm.nih.gov/24254885/
- A New Look at P-values https://evidence.nejm.org/doi/abs/10.1056/EVIDoa2300003
- PARAGON HF https://www.nejm.org/doi/full/10.1056/NEJMoa1908655
II. Interatrial Shunts for HF
No Net HF Benefit for Interarterial Shunt Device
https://www.medscape.com/viewarticle/no-net-hf-benefit-interarterial-shunt-device-2024a10006kk
- REDUCE LAP HF II https://doi.org/10.1016/S0140-6736(22)00016-2
III. Triglyceride Lowering
Early Olezarsen Results Show 50% Reduction in Triglycerides
https://www.medscape.com/viewarticle/early-olezarsen-results-show-50-reduction-triglycerides-2024a10006oz
Is It Time to Stop Treating High Triglycerides?
https://www.medscape.com/viewarticle/990126
- NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2402309
Substantial Triglyceride Reduction With Plozasiran
https://www.medscape.com/viewarticle/substantial-triglyceride-reduction-plozasiran-2024a10006wf?icd=login_success_email_match_norm
- JAMA Cardiology https://jamanetwork.com/journals/jamacardiology/article-abstract/2817469
IV. Diltiazem and Factor Xa inhibitors
- JAMA Vanderbilt University Paper https://jamanetwork.com/journals/jama/fullarticle/2817546
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
ACC Part 2: The TACT2 trial of chelation, inter-atrial shunts for HF, and triglyceride lowering; plus diltiazem and Factor Xa anticoagulants are the topics John Mandrola, MD, covers this week.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. TACT 2
Chelation Therapy Provides No Benefit Post-MI
https://www.medscape.com/viewarticle/chelation-therapy-provides-no-benefit-post-mi-2024a10006l5
Chelation Therapy and CV Risk: Why TACT2 Showed No Benefit https://www.medscape.com/viewarticle/chelation-therapy-and-cv-risk-why-tact2-showed-no-benefit-2024a1000761?src=
- JAMA TACT 1 paper https://jamanetwork.com/journals/jama/fullarticle/1672238
- Diabetes Subgroup paper https://pubmed.ncbi.nlm.nih.gov/24254885/
- A New Look at P-values https://evidence.nejm.org/doi/abs/10.1056/EVIDoa2300003
- PARAGON HF https://www.nejm.org/doi/full/10.1056/NEJMoa1908655
II. Interatrial Shunts for HF
No Net HF Benefit for Interarterial Shunt Device
https://www.medscape.com/viewarticle/no-net-hf-benefit-interarterial-shunt-device-2024a10006kk
- REDUCE LAP HF II https://doi.org/10.1016/S0140-6736(22)00016-2
III. Triglyceride Lowering
Early Olezarsen Results Show 50% Reduction in Triglycerides
https://www.medscape.com/viewarticle/early-olezarsen-results-show-50-reduction-triglycerides-2024a10006oz
Is It Time to Stop Treating High Triglycerides?
https://www.medscape.com/viewarticle/990126
- NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2402309
Substantial Triglyceride Reduction With Plozasiran
https://www.medscape.com/viewarticle/substantial-triglyceride-reduction-plozasiran-2024a10006wf?icd=login_success_email_match_norm
- JAMA Cardiology https://jamanetwork.com/journals/jamacardiology/article-abstract/2817469
IV. Diltiazem and Factor Xa inhibitors
- JAMA Vanderbilt University Paper https://jamanetwork.com/journals/jama/fullarticle/2817546
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
Previous Episode
Apr 12 2024 This Week in Cardiology
ACC Recap #1: DanGer Shock (plus a sobering JAMA research letter on Impella use), REDUCE-AMI, PREVENT, and EMPACT-MI are the topics John Mandrola, MD, covers in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. DanGer-Shock Trial
Impella CP Improves Survival in STEMI, Cardiogenic Shock https://www.medscape.com/viewarticle/impella-cp-improves-survival-stemi-cardiogenic-shock-2024a10006kz
Impella Saves Lives in Cardiogenic Shock, but Patient Selection Key https://www.medscape.com/viewarticle/1000659
- Published DanGer Shock Study https://www.nejm.org/doi/full/10.1056/NEJMoa2312572
- JAMA Research letter https://jamanetwork.com/journals/jama/article-abstract/2817457
II. REDUCE-AMI Trial
New Data Question Beta-Blockers Post-MI With Preserved EF https://www.medscape.com/viewarticle/new-data-question-beta-blockers-post-mi-preserved-ef-2024a10006y8
Beta-Blockers Post-MI Past Their Expiration Date: REDUCE-AMI https://www.medscape.com/viewarticle/1000663
- REDUCE-AMI paper https://www.nejm.org/doi/full/10.1056/NEJMoa2401479
- Meta-analysis: Beta Blockers for MI https://doi.org/10.1016/j.amjmed.2014.05.032
III. PREVENT Trial
Preventive PCI for Vulnerable Plaques Reduces Cardiac Events
https://www.medscape.com/viewarticle/preventive-pci-vulnerable-plaques-reduces-cardiac-events-2024a10006tc
Preventive Coronary Stents: Not There Yet
https://www.medscape.com/viewarticle/preventive-coronary-stents-not-there-yet-2024a10006yr
- PREVENT https://doi.org/10.1016/S0140-6736(24)00413-6
IV. EMPACT MI trial of Empagliflozin in the Post-MI setting
Empagliflozin Fails to Reduce Events After Acute MI
https://www.medscape.com/viewarticle/empagliflozin-fails-reduce-events-after-acute-mi-2024a10006kn
- EMPACT-MI: Another SGLT2 Inhibitor Miss in Post-MI Care https://www.medscape.com/viewarticle/1000684
- EMPACT MI https://www.nejm.org/doi/10.1056/NEJMoa2314051
- DAPA MI https://evidence.nejm.org/doi/full/10.1056/EVIDoa2300286
- PARADISE MI https://www.nejm.org/doi/full/10.1056/NEJMoa2104508
- Kaul thread https://x.com/kaulcsmc/status/1776611935842165029
- Kaul paper https://www.ahajournals.org/doi/full/10.1161/circulationaha.116.022537
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
Next Episode
Apr 26 2024 This Week in Cardiology
A listener defends colored boxes in guidelines; mysteries of non-culprit coronary lesions during PCI, and of AF ablation; and surrogate markers are the topics John Mandrola, MD, covers in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Mystery of What to Do in the Cath Lab after Fixing the Culprit Lesion – The FULL REVASC Trial
Complete Revascularization Not Superior to Culprit-Only PCI After MI
https://www.medscape.com/viewarticle/complete-revascularization-not-superior-culprit-only-pci-2024a10007ik
- FULL REVASC Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2314149
- FIRE Trial https://www.nejm.org/doi/10.1056/NEJMoa2300468
- COMPLETE Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1907775
- Cohen Tweet on FULL REVASC https://x.com/djc795/status/1781361606238085532
II. AF Ablation Mysteries
New Expert Consensus on Ablation Strategies for AF
https://www.medscape.com/viewarticle/new-expert-consensus-ablation-strategies-af-2024a1000851
- Bern Study of Remapping https://doi.org/10.1016/j.jacep.2024.02.026
- Natural History of SCAF https://doi.org/10.1016/j.jacc.2019.09.050
- Liverpool Study: Thermal PV Isolation in Persistent AF https://doi.org/10.1016/j.hrthm.2024.04.061
III. Surrogate Markers
- JAMA: Surrugate Markers and Clinical Outcomes https://jamanetwork.com/journals/jama/fullarticle/2817850
- BP Surrogate Meta-analysis https://doi.org/10.1016/S0140-6736(21)00590-0
- JAMA: Nonfatal MI as Surrogate for Mortality https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2785560
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
If you like this episode you’ll love
Episode Comments
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/this-week-in-cardiology-67209/apr-19-2024-this-week-in-cardiology-49356552"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to apr 19 2024 this week in cardiology on goodpods" style="width: 225px" /> </a>
Copy